Literature DB >> 25998153

miR‑365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer.

Min Li1, Lulu Liu1, Wenqiao Zang1, Yuanyuan Wang1, Yuwen Du1, Xiaonan Chen1, Ping Li2, Juan Li2, Guoqiang Zhao1.   

Abstract

MicroRNAs (miRNAs) have important roles in the initiation and progression of human cancer, including breast cancer. We evaluated miR‑365 expression in breast cancer tissues, and investigated its effects on cell growth, cell cycle, cell invasion, and expression of its target gene ADAMTS-1. miR‑365 expression levels were analyzed in breast cancer tissues and adjacent normal tissues using qRT-PCR. CCK-8, cell cycle, and invasion assays were used to explore the role of miR‑365 expression in breast cancer cells. We conducted luciferase reporter and western blot assays to test whether ADAMTS-1 is a direct target of miR‑365. We found that miR‑365 expression levels were significantly higher in breast cancer tissues compared with adjacent non-tumor tissues (P<0.05). These relatively high expression levels were significantly associated with advanced clinical stages (P<0.05). In breast cancer cell lines, transfection with miR‑365 inhibitor suppressed proliferation and invasion, and resulted in cell cycle arrest. Subsequent experiments indicated that miR‑365 bound the 3'-UTR of ADAMTS-1 and downregulated its expression. Our findings indicated that the inhibition of miR‑365 reduced cell proliferation and cell invasion. Additionally, miR‑365 may function as a novel oncogene in breast cancer through targeting ADAMTS-1. These findings provide insight into the mechanism of breast cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998153     DOI: 10.3892/ijo.2015.3015

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis.

Authors:  Yunfei Qu; Ning Zhang
Journal:  Exp Ther Med       Date:  2018-09-11       Impact factor: 2.447

2.  Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.

Authors:  Getinet M Adinew; Samia S Messeha; Equar Taka; Ramesh B Badisa; Lovely M Antonie; Karam F A Soliman
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

3.  Mechanism of miR-365 in regulating BDNF-TrkB signal axis of HFD/STZ induced diabetic nephropathy fibrosis and renal function.

Authors:  Peng Zhao; Xiaqiu Li; Yang Li; Jiaying Zhu; Yu Sun; Jianli Hong
Journal:  Int Urol Nephrol       Date:  2021-04-21       Impact factor: 2.370

4.  MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).

Authors:  Yong Zhu; Xing Wen; Peng Zhao
Journal:  Med Sci Monit       Date:  2018-06-02

5.  Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients.

Authors:  Yang Zhang; Jiannan Chen; Yu Wang; Dehua Wang; Weihui Cong; Bo Shiun Lai; Yi Zhao
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

6.  miR-548d-3p/TP53BP2 axis regulates the proliferation and apoptosis of breast cancer cells.

Authors:  Qiong Song; Jiangqiang Song; Qimin Wang; Yanling Ma; Nai Sun; Jieyu Ma; Qiu Chen; Guishan Xia; Yanping Huo; Longqiu Yang; Baolin Li
Journal:  Cancer Med       Date:  2015-12-13       Impact factor: 4.452

7.  MicroRNA-365 regulates IL-1β-induced catabolic factor expression by targeting HIF-2α in primary chondrocytes.

Authors:  Hyun Sook Hwang; Su Jin Park; Mi Hyun Lee; Hyun Ah Kim
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

8.  MicroRNA-365 promotes lung carcinogenesis by downregulating the USP33/SLIT2/ROBO1 signalling pathway.

Authors:  Yuhuan Wang; Shuhua Zhang; Hejing Bao; Shukun Mu; Baishen Zhang; Hao Ma; Shudong Ma
Journal:  Cancer Cell Int       Date:  2018-05-01       Impact factor: 5.722

9.  Analysis of the expression levels and clinical value of miR-365 and miR-25 in serum of patients with non-small cell lung cancer.

Authors:  Dongxuan Huang; Wenfang Ou; Huifen Tong; Ming Peng; Yamei Ou; Zeqing Song
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

10.  Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Authors:  Ines Stevic; Volkmar Müller; Karsten Weber; Peter A Fasching; Thomas Karn; Frederic Marmé; Christian Schem; Elmar Stickeler; Carsten Denkert; Marion van Mackelenbergh; Christoph Salat; Andreas Schneeweiss; Klaus Pantel; Sibylle Loibl; Michael Untch; Heidi Schwarzenbach
Journal:  BMC Med       Date:  2018-10-10       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.